Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

Alessio Danilo Inchingolo 1,†, Giuseppina Malcangi 1,†, Sabino Ceci 1,†, Assunta Patano 1,†, Alberto Corriero 2,†, Daniela Azzollini 1, Grazia Marinielli 1, Giovanni Coloccia 1, Fabio Piras 1, Giuseppe Barile 1, Vito Settanni 1, Antonio Mancini 1, Nicole De Leonardis 1, Grazia Garofoli 1, Giulia Palmieri 1, Ciro Gargiulo Isacco 1, Biagio Rapone 1,†, Megan Jones 1, Ioana Roxana Bordea 3,*,‡, Gianluca Martino Tartaglia 4, Antonio Scarano 5, Felice Lorussi 5, Luigi Macchia 6, Angela Maria Vittoria Larocca 7, Silvio Tafuri 8, Giovanni Migliore 9, Nicola Brienza 2,4, Gianna Dipalma 1,† and Francesco Inchingolo 1,*,†

1 Department of Interdisciplinary Medicine, Section of Dental Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
2 Department of Interdisciplinary Medicine, Intensive Care Unit Section, Aldo Moro University, 70121 Bari, Italy
3 Department of Oral Rehabilitation, Faculty of Dentistry, Luigi Hatiegenau University of Medicine and Pharmacy, 40012 Cluj-Napoca, Romania
4 UOC Maxillo-Facial Surgery and Dentistry, Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, University of Milan, 20100 Milan, Italy
5 Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 60100 Chieti, Italy
6 Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari “Aldo Moro”, 70124 Bari, Italy
7 Hygiene Complex Operating Unit, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Place Giulio Cesare, 11, 70124 Bari, Italy
8 Department of Biomedical Science and Human Oncology, University of Bari, 70121 Bari, Italy
9 University Hospital of Bari, 70120 Bari, Italy

* Correspondence: biagiorapone79@gmail.com (B.R.); roxana.bordea@gmail.com (I.R.B.); dlrorussofelice@gmail.com (F.L.); francesco.inchingolo@uniba.it (F.I.); Tel.: +39-3477619817 (B.R.); +40-744919319 (I.R.B.); +39-3282132586 (F.L.); +39-331211104 (F.I.)
† These authors contributed equally to this work as last authors.
‡ These authors contributed equally to this work as first authors.

Abstract: The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood group, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRNA Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group O, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab...
controls were performed every 15th of the month continuously. However, the enrolled patients’ activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari “Aldo Moro” led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.

Keywords: MERS; SARS-CoV-2; SARS-CoV-1; COVID-19; antibodies; antispike; vaccines; dentistry; Pfizer; booster

1. Introduction

SARS-CoV-2 represents a viral vector with a very critical airborne transmission capability [1,2]. In fact, the air droplets’ release seems to be one of the most effective diffusion ways for COVID-19 infection [3]. Therefore, many authors indicated healthcare workers and dentists as very critical subjects for viral vector exposure due to the medical environment and the prolonged contact with potentially infected patients [4,5]. In fact, this condition seems to be associated with a confined working environment with lots of aerosol generation and risk of being infected from salivary droplets which contain the SARS-CoV-2 virus [5–7].

Many studies have demonstrated that after infection, a decline in serum anti-SARS-CoV-2 antibodies occurs, decreasing rapidly in the first 120 days after infection and then more slowly in the following 210 days while maintaining significant antibody levels for at least 11 months after infection [8–12]. In an analysis of 3689 adults aged ≥18 years who were admitted to 21 US hospitals in 18 states from 11 March to 15 August 2021, the efficacy values of Moderna and Pfizer-BioNTech mRNA vaccines (VE) and Jannsen vaccine were assessed. Values were estimated at 15–40 days after receiving the second dose of Moderna and Pfizer-BioNTech vaccine or the single dose of Jannsen vaccine [13]. The EV levels were 93% for Moderna and 88% for Pfizer, respectively, while the single dose Janssen vaccine had a slightly lower EV of 71%. These results suggest that the double-dose protection of the mRNA vaccines (Pfizer-BioNTech and Moderna) is greater than the 1-dose Janssen. Moderna vaccine showed an efficacy of 93% at 2–17 weeks (median = 66 days) after receiving the second dose of vaccine and 92% at >17 weeks (median = 141 days) (p = 1.000). In contrast, the Pfizer-BioNTech vaccine showed a significantly reduced VE of 91% (median = 69 days) and 77% (median = 143 days), respectively. Moderna also produced higher levels of post-vaccination anti-RBD antibodies than the Pfizer-BioNTech vaccine. The VE of the Moderna vaccine is better than Pfizer-BioNTech vaccines, because the mRNA content in the Moderna vaccine is greater, as are the time intervals between doses (28 days for Moderna and 21 days for Pfizer) [14,15]. However, in this study, variant-specific VE, including Delta variants (B.1.617.2 and AY underlines), were not assessed. In another study of 3975 healthcare personnel, 204 (5%) were positive for SARS-CoV-2, of which 5 were vaccinated ≥2 weeks after the second dose, 11 were partially vaccinated ≥2 weeks after the first dose and <2 weeks after the second dose, and 156 were not vaccinated. Persons (5%) became infected. Vaccine efficacy was 91% with full vaccination and 81% with partial vaccination. In addition, in partially or fully vaccinated infected subjects, the mean viral RNA load was 40% lower than in unvaccinated subjects, as well as 58% fewer febrile symptoms and a shorter illness of 2.3 days [14]. The VE of the mRNA vaccines towards the Delta variant were reduced, and this was higher than in the Pfizer vaccine (Moderna 76%, Pfizer 42%) [16,17]. In conclusion, however, the data ensure that all COVID-19 vaccines approved or self-released by the FDA ensured substantial defense against hospitalization for COVID-19 at 99% [18]. The association of the improved antibody response linked to the longer time interval between the first and second administration (see Moderna/Pfizer)
can be correlated to the concept of the binding energy or receptor affinity that a B-cell has for a given antigen. This is the same affinity as the antibodies secreted by the same B-cell after antigenic stimulation. Thus, with the attendance of small doses of antigen, cells with high-affinity receptors will be stimulated more, resulting in the secretion of high-affinity antibodies. Conversely, larger doses of antigen will induce lower affinity antibodies. This relationship between immunogen dose and antibody affinity explains why, as time passes after immunization and the concentration of antigen in the body decreases, antibody affinity increases. Since it is mainly B cells with high affinity receptors that are stimulated, the average affinity of antibodies in the serum increases. The attendance of antibodies aids this selection by competing with cellular receptors for the antigen. During the secondary response, the increased affinity of the antibodies may be because of the stimulation of B cells with high affinity receptors, which occurred during the primary response when antigen concentrations were progressively decreasing over time. It is hypothesized that the secondary response would result from the stimulation of cells qualitatively different from those of the primary response [17,19–25]. The role of the booster dose of the primary cycle is to achieve a greater immune response and to ensure a good level of defense against infection [26]. The main goal of immunization during the COVID-19 pandemic is to improve the clinical course by avoiding hospitalization and reducing mortality. Therefore, the third dose should only be done if it is clear that there is no protection against these disease outcomes of the disease over time. According to the CDC (Center for Disease Control and Prevention) recipients of the COVID-19 vaccine who can get booster shots (Pfizer-BioNTech or Moderna COVID-19 vaccine) are [27]:

- Elderly 65 years of age or older: people aged 65 and over should receive a booster injection. The risk of severe COVID-19 disease increases with age.
- Long-term care facility residents aged 18 and over: Long-term care facility residents live closely together in group settings.
- People with comorbidities between the ages of 18 and 64.
- People who work or live in high-risk environments between the ages of 18 and 64.

The FDA and CDC suggest a booster dose at least 4 weeks after the second dose of Moderna or Pfizer, or 60 days after the first dose of Janssen/Johnson & Johnson for people who have comorbidities associated with immunosuppression [28–32]. On 30 July 2021, Israel became the first to give a booster dose of Pfizer against COVID-19 to all persons aged over 60 years who had been immunized at least 150 days previously. At 2 weeks after the booster dose, there was an 11.4-fold chance of infection and a >10-fold lower chance of severe disease. Against the Delta variant, the efficacy of Pfizer’s third dose was about 95%, a similar value to the efficacy of the original vaccine, which had been reduced from 85% to 75% against severe forms [33]. The EMA is evaluating the use of the third dose for Moderna. Data from the pharmaceutical company’s studies have shown significant anti-pal responses 15 days after the third dose of the Moderna vaccine (a 50 microgram booster dose of mRNA-1273): more than 40-fold against the Delta variant (B.1.617.2), 32-fold against Beta (B.1.351), and 43.6-fold against Gamma (P.1). In addition, the reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine was analyzed. A study conducted on seniors and immunocompromised individuals reported that local and systemic side effects were analogue to those who received prior doses. [34] Bensouna et al. analyzed the humoral immunity after a booster dose of Pfizer in 69 persons cured with either hemodialysis or peritoneal dialysis. In this analysis, the third dose was performed at least four weeks after the second dose. Results showed a substantial rise in the antibody level in the sample. However, there was not a significant rise in the antibody level after a booster dose in persons who were undergoing chemotherapy or in those with initial high anti-S1 antibodies [35]. The target of the present investigation was to assess the short and long term immune profiling vaccine response in healthcare workers.
2. Materials and Methods

2.1. General Characteristics

Since March 2020, the staff involved in patient care has undergone periodic screening with molecular tests for SARS-CoV-2 infection at the university hospital consortium polyclinic of Bari. Subsequently, the vaccination campaign with the vaccine BNT162b2 mRNA COVID-19 (Pfizer, New York, NY, USA) began at the same institution. For the purposes of this analysis, hospital staff were asked to assess antibody dynamics after vaccination. In this analysis, 230 healthcare workers from different departments were included (90 dentistry, 72 radiology, 34 forensic medicine, 34 internal medicine) of which 23 operators contracted SARS-CoV-2. The health care groups evaluated belong to 4 areas:

- dental area: dental physicians, chair assistants, hygienists, and nurses: a total of 90 were evaluated. (39.13% of 230 total)
- radiological area: radiology physicians, technicians, and nurses: a total of 72 were evaluated (31.30% of a total of 230)
- internal medicine area: a total of 34 were evaluated (14.78% of a total of 230);
- Forensic Medicine area: a total of 34 (14.78% of 230 total) were evaluated.

In order to estimate the antibody titer decay the sample population was categorized into 4 different classes of age range:

- Group I: subjects between 20–30 years old;
- Group II: subjects between 30–40 years old;
- Group III: subjects between 40–50 years old;
- Group IV: subjects between 50–60 years old;
- Group V: subjects between 60–70 years old;

The antibody levels of the recruited healthcare workers were evaluated. Overall, the antibody response was assessed circa ten months after vaccination. Anti-SARS-CoV-2 Spike IgG antibodies were assessed with the LIAISON® SARS-CoV-2 TrimericS IgG assay (DiaSorin, Saluggia, Italy), which can show both binding and neutralizing antibodies to the trimeric Spike glycoprotein. Subjects were engaged from 11 January 2021 (first dose) and 3 February 2021 (second dose). The occurrence of vaccine-associated viral infections was assessed by RT-PCR on symptomatic/contact cases through 30 September 2021. All health care workers enrolled in the research were given a nasopharyngeal swab every 15th of each month to assess the onset of COVID-19 after the second vaccine. All enrolled in the research always performed swabs every 15th of the month starting in May 2020. Therefore, the enrolled healthcare workers were screened and did not contract SARS-CoV-2 already from 15 May 2020. The last sampling for assessing the antibody levels was carried out 270 days after the first dose of the Pfizer vaccine. The subjects enrolled in the analysis were monitored with molecular swab on the 15th of each month and none were positive. Thus, the registered healthcare professionals had all been screened and certainly did not contract SARS-CoV-2.

2.2. Statistical Analysis

The sample size calculation was performed considering an effect size $\hat{\delta}^2$: 0.05; $\alpha$ error: 0.05 and power (1- $\beta$): 0.80, and 3 predictors. The determined population output was 222 subjects which was increased by 4% as an eventual drop-out compensation.

Descriptive statistical analysis was conducted by the program Microsoft Excel (Microsoft, Redmond, WA, USA) by calculating the average, max, and min level of the antibody titers for different groups of patients by blood type, number of vaccination shots, titers test titers, gender and age, as well as the correlation coefficients by test titers. The normal distribution of the study data was assessed through the Kolmgorov–Smirnov test. The Kruskal–Wallis followed by the Dunn’s post-hoc test was conducted to evaluate the mean differences of the study groups.

The level of significance was $p < 0.05$. 

3. Results

All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispark IgG level above 500 BAU/mL at the first antispark protein Essay (2 months after the second dose on 3 April 2021): 100% of personnel had anti-S IgG titers ≥2000 BAU/mL, 19.2% between 1500–2000 BAU/mL, 9.8% between 1000–1500 BAU/mL, and 3.4% ≤1000 BAU/mL (Figure 1A).

![Graph showing IgG levels](image)

Figure 1. (A): Percentage of enrolled persons at the first titer below and above the 1000 BAU/mL threshold of antispark IgG. (B): Percentage of enrolled persons at the second titer below and above the 500 BAU/mL threshold of antispark IgG. (C): Percentage of enrolled persons at the third titer below and above the 500 BAU/mL threshold of antispark IgG.

At the second titer (75 days after the first titer on 20 June 2021) 4 (1.7% of 230 enrolled) patients showed antispark IgG level under 500 BAU/mL. (Figure 1B). At the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose) 37 (16.1% of 230 enrolled) patients showed antispark IgG level under 500 BAU/mL; this percentage adds to the 1.7% of the second titer for a total 17.8% that fell below the above threshold. (Figure 1C). Seven months after the conclusion of the vaccination program, only one subject (0.43% of 230 enrolled) had SARS-CoV-2 infection, but without any symptoms and negativization after 15 days. Our descriptive analysis (Figures 1 and 2) points to the fact that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest titer of antibodies compared to group A, B, and AB in each of the three titers (Figure 1 and Table 1). Age range of the analysis was the following (Figure 2):

1. Between the age of 20 and 30 years old there were 45 subjects (19.57% of 230 enrolled).
2. Between the age of 30 and 40 years old there were 52 subjects (22.61% of 230 enrolled).
3. Between the age of 40 and 50 years old there were 34 subjects (14.78% of 230 enrolled).
4. Between the age 50 and 60 years old there were 53 subjects (23.04% of 230 enrolled).
5. Between the age of 60 and 70 years of age there were 46 subjects (20% of 230 enrolled).
Between the age of 60 and 70 years of age there were 46 subjects (20% of 230 enrolled).

Figure 2. Age distribution of enrolled patients.

Table 1. Results for all blood types.

| All Blood Types | Titer 1  | Titer 2  | Titer 3  |
|-----------------|----------|----------|----------|
| Average         | 8.413    | 3.880    | 1.473    |
| St.Dev          | 9.510    | 5.156    | 1.818    |
| Max             | 64.771   | 44.352   | 15.455   |
| Min             | 882      | 103      | 77       |
| Range           | 63.889   | 44.249   | 15.377   |
| # Patients      | 229      |          |          |
| Correlation     | 0.97     | 0.80     | 0.81     |

In the age group between 50 and 60, we detected an increase of antibody levels in all three titers compared to the other groups, which showed instead approximately close average antibody levels between the different titers (Figures 3–6). No dependency with the antibodies level was found on gender (Figure 7, Tables 2 and 3).

3.1. Statistical Findings

3.1.1. Age-Related Findings

Group I showed antispike IgG level means and standard deviations of 6342 ± 5506 BAU/mL at titer 1, 2207 ± 2397 BAU/mL at titer 2, and 207.6 ± 599.8 BAU/mL at titer 3 (Table 4). The antispike IgG level of group II reported a 5118 ± 6593 BAU/mL at titer 1, 1628 ± 2041 BAU/mL at titer 2, and 151.3 ± 377.0 BAU/mL at titer 3. Group III showed 3871 ± 4737 BAU/mL at titer 1, 1172 ± 1522 BAU/mL at titer 2, and 169.0 ± 414.3 BAU/mL at titer 3. Group IV reported an antispike IgG level of 4046 ± 4174 BAU/mL at titer 1, 1963 ± 3872 BAU/mL at titer 2, and 1010 ± 3413 BAU/mL at titer 3. Group V showed 6438 ± 10,573 BAU/mL at titer 1, 2289 ± 5513 BAU/mL at titer 2, and 780.6 ± 2578 BAU/mL at titer 3 (Table 4). A significant difference was detected between groups I, II, IV, and V between the antispike IgG level at titer 1 (p < 0.05), 2, and 3, while a lower antispike IgG decrease was detected between the titer 1 and 2 of group III (p > 0.05) (Figure 8). The comparison of antispike IgG level titer 1, 2, and 3 showed no statistically significant differences between all age groups (p < 0.06) (Figure 7).
Figure 3. Average, max, and min titers of antibodies for the entire sample.

Figure 4. Average, max, and min titers of antibodies by blood type regardless of rhesus factor.
Figure 4. Average, max, and min titers of antibodies by blood type regardless of rhesus factor.

Figure 5. Dynamics of average levels of antibodies by age.

Figure 6. Average levels of antibodies for males and females.

Figure 5. Dynamics of average levels of antibodies by age.

Figure 6. Average levels of antibodies for males and females.
Figure 6. Average levels of antibodies for males and females.

Figure 7. Chart of the antispike IgG level referred to all age groups.

Table 2. Results for all ages.

| Ages Related Blood Types | Titer 1 | Titer 2 | Titer 3 |
|--------------------------|---------|---------|---------|
| Average                  | 8.413   | 3.880   | 1.473   |
| St.Dev                   | 9.510   | 5.156   | 1.818   |
| Max                      | 64.771  | 44.352  | 15.455  |
| Min                      | 882     | 103     | 77      |
| Range                    | 63.889  | 44.249  | 15.377  |
| # Patients               | 229     |         |         |
| Correlation              | 0.97    | 0.80    | 0.81    |

Table 3. Blood types referred to all genders.

| Genders Referred Blood Types | Titer 1 | Titer 2 | Titer 3 |
|-----------------------------|---------|---------|---------|
| Average                     | 8.413   | 3.880   | 1.473   |
| St.Dev                      | 9.510   | 5.156   | 1.818   |
| Max                         | 64.771  | 44.352  | 15.455  |
| Min                         | 882     | 103     | 77      |
| Range                       | 63.889  | 44.249  | 15.377  |
| # Patients                  | 229     |         |         |
| Correlation                 | 0.97    | 0.80    | 0.81    |
Table 4. Antispike IgG level referred to all age groups.

|               | Group I 20–30 yo | Group II 31–40 yo | Group III 41–50 yo | Group IV 51–60 yo | Group V 61–70 yo |
|---------------|-----------------|------------------|-------------------|------------------|-----------------|
| titer 1       | 6342            | 1628             | 3871              | 4046             | 6438            |
| titer 2       | 2207            | 1628             | 1172              | 1963             | 2289            |
| titer 3       | 207.6           | 151.3            | 169.0             | 1010             | 780.6           |
| Mean          | 5506            | 2041             | 4737              | 4174             | 5513            |
| SD            | 599.8           | 377.0            | 1522              | 3872             | 10673           |
| Lower 95% CI  | 4668            | 2243             | 657.3             | 2896             | 6438            |
| Upper 95% CI  | 8016            | 2202             | 1687              | 3030             | 9608            |
3.1.2. Blood-Type-Related Findings

Group 0/+ type showed antispike IgG level means and standard deviations of 10,289 ± 10,013 BAU/mL at titer 1, 5025 ± 6024 BAU/mL at titer 2, and 1739 ± 15.48 BAU/mL at titer 3 (Figure 8; Table 5). The antispike IgG level of 0/− type group reported a 16,810 ± 15,992 BAU/mL at titer 1, 8710 ± 9160 BAU/mL at titer 2, and 1561 ± 4414 BAU/mL at titer 3. The A/+ group III showed 7327 ± 8160 BAU/mL at titer 1, 3159 ± 3748 BAU/mL at titer 2, and 1246 ± 1291 BAU/mL at titer 3. Group A/− type reported an antispike IgG level of 5717 ± 3095 BAU/mL at titer 1, 2666 ± 2138 BAU/mL at titer 2, and 872.8 ± 333.2 BAU/mL at titer 3. The B/+ blood type group showed 5867 ± 7293 BAU/mL at titer 1, 2574 ± 2965 BAU/mL at titer 2, and 1167 ± 1142 BAU/mL at titer 3 (Table 5). The antispike IgG level of the B/− type group reported 9862 ± 5421 BAU/mL at titer 1, 4387 ± 2881 BAU/mL at titer 2, and 1873 ± 1435 BAU/mL at titer 3. The antispike IgG level of the AB/+ type group reported 4945 ± 3577 BAU/mL at titer 1, 2193 ± 1625 BAU/mL at titer 2, and 876.8 ± 397.4 BAU/mL at titer 3. A significant difference has been detected between the antispike IgG level comparing the titer 1, 2, and 3 for all blood type groups (p < 0.05). The stratified comparison of the antispike IgG titer level showed no statistically significant differences between all blood type groups (p < 0.05).

Table 5. Antispike IgG level referred to the blood type groups.

|                | 0/+              | 0/−               |
|----------------|------------------|-------------------|
| Titer 1        | Titer 2          | Titer 3           | Titer 1 | Titer 2 | Titer 3 |
| Mean           | 10,289           | 5025              | 1739    | 16,810 | 8710    | 3561    |
| SD             | 10,013           | 6024              | 1548    | 15,992 | 9160    | 4414    |
| Lower 95% CI of mean | 8001            | 3648              | 1385    | 27.84  | 903     | −1071   |
| Upper 95% CI   | 12,577           | 6401              | 2093    | 33,593 | 18,322  | 8192    |
| A/+            |                 |                   |         |        |         |         |
| Titer 1        | Titer 1          | Titer 1           | Titer 1 | Titer 1 | Titer 2 | Titer 3 |
| Mean           | 7327            | 5717              | 5717    | 5717    | 8710    | 3561    |
| SD             | 8160            | 3095              | 3095    | 3095    | 9160    | 4414    |
| Lower 95% CI of mean | 5008            | 3638              | 3638    | 3638    | 903     | −1071   |
| Upper 95% CI   | 9646            | 7797              | 7797    | 7797    | 18,322  | 8192    |
Table 5. Cont.

|                  | B/+ | Titer 1 | Titer 2 | B/- | Titer 1 | Titer 2 |
|------------------|-----|---------|---------|-----|---------|---------|
| Mean             | 5867|         |         | 5867|         |         |
| SD               | 7293|         |         | 7293|         |         |
| Lower 95% CI of mean | 2856|         |         | 2856|         |         |
| Upper 95% CI     | 8877|         |         | 8877|         |         |

|                  | AB/+ | Titer 1 |
|------------------|------|---------|
| Mean             | 4945|
| SD               | 3577|
| Lower 95% CI of mean | 2672|
| Upper 95% CI     | 7218|

4. Discussion

The population sampling of the present investigation was conducted in order to include according to a more equal distribution healthcare workers from a medical/surgical interventional area and doctors from a non-interventional medical area. The differences of healthcare work exposure could produce a sensible critical point in the population enrollment and a potential limit of the study. On the contrary, this approach is able to produce a more consistent sample size and consequently a higher statistical power.

Immunological memory is a property of both T and B lymphocytes [4,36–39]. In an antiviral response, cytotoxic T lymphocytes selectively eliminate the infected cells; neutralizing antibodies secreted by plasma cells preventing the virus from infecting them [37,40–52]. Virus-specific T helper cells are required to generate immunological memory, particularly for long-lasting bone marrow plasma cells (BMPC), which secrete antiviral antibodies when the virus has disappeared for long-lasting immunity [28,36,53–61]. The bone marrow (BM) is one of the main immunological organs in the human body. BMPCs are detected in the BM and in gut-associated lymphoid tissues (GALT), which produce antibodies for a lot of time [40,62]. Studying the serum values of patients convalescing from COVID-19 at 1, 4, 7, and 11 months, it was detected that infection with SARS-CoV-2 provokes a transient and early response with a high production of extrafollicular (spleen and lymph nodes) antibodies, which decrease relatively quickly [63–66]. Subsequently, more stable serum antibodies secreted by long-lasting BMPC are detected. In fact, analysis of bone marrow aspirates obtained approximately 7 and 11 months post-infection revealed S-specific anti-SARS-CoV-2 BMPC [67–70]. Consequently, circulating anti-S IgG titers at 210–240 days after symptom begin in convalescent individuals is related with the concentration of anti-S IgG BMPC present in the bone marrow aspirate [40,62]. All convalescent subjects who received a dose of mRNA vaccine increased all components of the humoral reaction. The data confirm that BMPC expressing specific antibodies are long-lasting, have serum neutralizing activity against new variants of concern, and are cleared and produced extensively after vaccination. These data suggest that immunity in convalescent persons will be very long-lasting. Individuals who contracted COVID-19 and received mRNA vaccines will produce antibodies and memory B cells that will also be protective against circulating SARS-CoV-2 variants [71–75]. Research at the Washington University School of Medicine in St Louis, Missouri, on the value of the memory B-cell response, analyzed fragments from the lymph nodes of vaccinated patients and found ‘germinal centres’, i.e., tiny areas of B-cell refinement, which, over time, synthesized increasingly powerful immune cells, thus being able, through this evolutionary process, to fight the Delta variant and other worrying SARS-CoV-2 variants. The persistence of these germinal centers was detected at 15 weeks post immunization [13].

Our study discovered that after 270 days after the second dose, most of the enrolled patients still showed a significant antispike titer. This is in contrast with what Yinon M.
Bar-On et al. showed in their analysis [76]. We think that antispike titers greater than 500 BAU/mL can still deliver protection as it should be noted that a decline in serum antibodies does not mean that there is a lowering of immunity but rather a rising of it with the development and persistence of SARS-CoV-2 memory CD8+ T cells, SARS-CoV-2 memory B Cells and SARS-CoV-2 memory CD4+ T cells in the bone marrow [77]. According to the age variable, no significant differences were detected between the study groups at titers 1, 2, and 3 ($p > 0.05$). In fact, the groups seemed to produce similar fluctuations and a consistent decrease in the antispike IgG levels. Similar evidence was detected according to the blood type groups that only the O negative blood groups seemed to produce a more consistent level of antispike IgG ($p < 0.05$) at titer 1 and titer 2. No differences in titer 3 were detected between the blood types in the present investigation ($p > 0.05$). This correlation with COVID-19 protection activity has been suggested by several authors but the association is not completely cleared and is controversial according to the current literature. In addition, very few data are reported in relation to the vaccination effectiveness. Rana et al. reported on a single center study that the A, B, and Rh+ blood groups were susceptible to COVID-19 infection in comparison to blood groups O and Rh− [78]. Very similar findings were reported on different populations groups such as household and children [79].

Certain subsets of individuals might also carry some form of protection having a much higher antibody’s titer compared to other subsets: in our study, we demonstrated that patients belonging to group zero may have this “enhanced” protection due to a higher antispike titer that lasts longer over time. The subset of patients aged 50–60 might have this increase in antibodies’ level because of some undetected comorbidity that in our hypothesis could lead to this immunological picture. Any other study at the moment does not support this finding. No dependency with the antibodies’ level was found with gender. This is in contrast with what Shachor-Meyouhas et al. [80] showed in their analysis where the male sex was identified as a risk factor for lower antibody level in an observational timeline of 3 months after the second shot. The strength of our analysis is that it extended over 9 months after the second shot. The COVID-19 vaccine booster shot should therefore be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient. It must be hence noted that the majority of the subjects enrolled in our study were protected against COVID-19 even after 9 months after the first dose of the vaccine despite their activity being a high risk because they carried out medical, dental, and surgical activities, and with droplets of water vaporized by the effect of turbines, piezosurgery. More studies are required to assess waning immunity kinetics in specific subsets of persons with specific traits such as comorbidities and other anamnestic data.

In healthy adults, two 30 µg doses of BNT162b2 elicited high neutralizing titers and robust, antigen-specific CD4+ and CD8+ T cell responses against SARS-CoV-2 [57,58]. Therefore, it revealed 95% efficacy among phase 2–3 study subjects aged 16 years or older [57]. Although BNT162b2 is a two-dose regimen, early protection after a single dose has been reported in clinical trials and based on real data [59,60]. A significant titer decay has been detected by Israel et al. [81] in a preliminary report on a wide population screening on BNT162b2 vaccinated subjects, reporting different antibody kinetics between vaccinated patients and convalescents. At 6 months after vaccination the 16.1% patients reported an antibody titer below the seropositivity threshold of <50 AU/mL, while 10.8% convalescent subjects were below <50 AU/mL 9 months after COVID-19 infection. A high titer of autoimmune antibodies in COVID-19 patients has been registered, although it is not clear how these antibodies help in the progression of the disease and its clinical picture. These antibodies were studied in a retrospective study of 115 hospitalized COVID-19 patients who had different clinical manifestations; the reaction of autoimmune antibodies to common antigens such as erythrocyte lysate, lipid phosphatidylserine (PS), and DNA was tested. In up to 36% of patients, a large quantity of IgG autoantibodies against erythrocyte lysate was detected.
Anti-DNA and anti-PS antibodies recorded when the patients were admitted to hospital showed an interconnection with the severity of the disease: the positive predictive values were 85.7 and 92.8, respectively. Persons with good values for at least one of the two autoantibodies were rated at 24% of the total severe cases. Recent studies reveal that coagulation, neutrophil levels, markers of cell damage, and erythrocyte size are strongly correlated with anti-DNA antibodies. Anti-DNA and anti-PS autoantibodies can potentially be considered predictive biomarkers in the typology of a clinical course of COVID-19. Long COVIDs are those who present with the persistence of symptoms or the development of new symptoms related to SARS-CoV-2 infection, at least 28 days after diagnosis. Symptoms may be constant or intermittent and may be multi-organ [82]. Dyspnea, tachycardia, and extreme tiredness are more frequent despite the normalization of the inflammatory parameters. Negative RT-PCR diagnostic test values, undoubtedly related to fibrosis induced by cytokine storms in the acute phase, led to chronic pulmonary and cardiac damage, with reduced flow in spirometry tests, high titer of troponin T (TroT), and brain natriuretic peptide (BNP). There are values thought to be because of fibrosis remodeling with transforming growth factor (TGF)-beta secretion in the chronic phase, with overlapping results in other diagnostic tests (ultrasound or chest CT) [83–85]. Symptoms include night sweats, temperature changes, gastrointestinal tract disorders [86], constipation/soft stools and peripheral vasoconstriction due to autonomic nervous system dysfunction [87]. In a study at the Policlinico Universitario di Bari, the characteristics and risk factors of 35-day long COVID (35-LC) were investigated over one year from 8 March 2020 to 15 March 2021. The analysis assessed the age, gender, and symptom characteristics of the first week. A distinction was made between persons with a short course of infection (less than 10 days) (<10 days COVID) and those who had been symptomatic for at least 28 days (28 days COVID or 28-LC). Adverse outcomes were not shown to be localized. Instead, they were present in several systems, including the immune system (e.g., Guillain-Barré syndrome, rheumatoid arthritis, pediatric multisystem inflammatory syndromes, such as Kawasaki disease), and the hematological system (vascular hemostasis), depression and anxiety and a condition called ‘brain fog’, which causes difficulties in attention and concentration. Molecular mechanisms associated with these disease outcomes/symptoms have been correlated [88].

Under well-being conditions, the host’s microbiome/virome [89] ecosystem is held in check by an effective host immune defense and persists in a state of equilibrium or homeostasis. In fact, dysbiosis leads to dozens of chronic metabolic changes [90]. Microbiome/virome dysbiosis may favor the growth of opportunistic pathogens. Immune dysregulation induced by SARS-CoV-2 may lead to an imbalance in the body’s existing microbial and viral ecosystems that may cause long-term multi-thyroid functional alterations with multiple symptoms [91]. In fact, almost all organisms in human microbiome/virome communities are ‘pathobionts’, namely they are able to change their gene pool to become pathogenic organisms under conditions of unbalance and immunosuppression [92]. It is also possible that, after becoming infected, SARS-CoV-2 persists in certain parts of the body or tissues in some persons, causing chronic symptoms [93–95].

5. Conclusions

The present study findings seems to suggest no differences of the different variables evaluated among the selected population groups. Blood groups A, B, and Rh+ seem to produce a similar response to the vaccination treatment with similar trends in a medium-short follow up. Blood groups O— seem to indicate an higher antispike IgG titer medium-short terms that could potentially support the higher protection against the SARS-CoV-2 infection. Therefore, long term studies with a larger sample size are needed to assess the relationship of between blood groups and the response to the SARS-CoV-2 vaccines.
**Author Contributions:** Conceptualization, A.D.I., G.D., F.L., A.S., S.T., B.R., A.M.V.L., S.C., A.P., A.C., L.M., G.M.T. and F.I.; methodology, A.D.I., I.R.B., F.P., G.B., V.S., A.M., G.C., F.L., I.R.B., S.T., G.M. (Giovanni Migliore), G.G., G.P., B.R. and L.M.; software, I.R.B., F.L., A.S., A.D.I., C.G.I., G.M. (Giuseppina Malcangi), G.C., M.J. and N.B.; validation, F.I., F.L., A.M.V.L., A.D.I., I.R.B., B.R., N.B. and N.D.L.; formal analysis, S.C., A.C., F.L., C.G.I., A.M., G.M. (Grazia Marinelli), and A.D.I.; investigation, G.M. (Giuseppina Malcangi), G.D., A.D.I., F.L., S.C., L.M., G.C., A.C., A.S. and F.I.; resources, A.D.I., I.R.B., N.D.L., G.P., G.M. (Grazia Marinelli), A.S., G.M. (Giovanni Migliore), M.J. and G.M. (Giuseppina Malcangi); data curation, D.A., A.S., G.M. (Giuseppina Malcangi), F.I. and G.M. (Grazia Marinelli); writing original draft preparation, A.D.I., G.D., S.C., L.M., A.C., A.P., F.L., I.R.B., G.M. (Giuseppina Malcangi), B.R., A.D.I. and F.I.; writing review and editing, F.I., F.L., I.R.B., B.R., N.B., G.M. (Giuseppe Malcangi), M.J., A.S. and M.J.; visualization, F.L., A.S., F.I. and I.R.B.; supervision, F.I., F.L., N.B., S.C., A.S. and A.C.; project administration, F.I., F.L., M.M., B.R., G.M. (Giuseppe Malcangi), A.S., F.L., A.D.I., G.D., A.D.I. and N.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local ethics committee of University of Bari Aldo Moro, Bari, Italy (reference number 2022/7228). The patients signed a written informed consent form.

**Informed Consent Statement:** Informed consent was obtained from the subjects involved in the study. Written informed consent was obtained from the patients to publish this paper.

**Data Availability Statement:** All experimental data to support the findings of this study are available upon request by contacting the corresponding author. The authors have annotated the entire data-building process and empirical techniques presented in the paper.

**Acknowledgments:** The authors thanks for the cooperation to Luigi Vimercati, Arnaldo Scardapane, Luigi Curatoli, Nicola Antonio Adolfo Quaranta, Maria Massaro, Mario Ribezi; Ludovica Nucci; Sergey Khachatur Aityan, Angelo Michele Inchingolo, Pasquale Stefanizzi; Damiano Nenore.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- **ACE2** angiotensin-converting enzyme-2
- **ACE** angiotensin-converting enzyme
- **ACE1** angiotensin-converting enzyme 1
- **AIFA** Agenzia Italiana del Farmaco
- **Alfa** English variant B.1.1.7
- **anti-RBD IgG** Immunoglobulin G anti receptor-binding domain
- **Antispike** Test IgG Antispike
- **BAU** unità arbitrarie vincolanti
- **Beta variant** (former of South Africa)
- **BMI** Body mass index
- **CI** Interval of confidence
- **CLIA** chemiluminescence immunoassay
- **CRP** C-reactive protein
- **Delta** Indian variant B.1.617.2
- **ELISA** enzyme-linked immunosorbent assay
- **EMA** European Medicines Agency
- **ETA** variant B.1.525; Date of designation March 2021
- **Gamma** Brasilian variant P.1
- **hACE2 receptor** human angiotensin I-converting enzyme 2 receptor
- **IFN** Interferon
- **IgA** Immunoglobulins A
- **IgG** Immunoglobulins G
- **IgM** Immunoglobulins M
IOTA variant B.1.526; earliest documented samples USA (November 2020), Date of designation March 2021

IQR Interquartile range

KAPPA Indian variant B.1.617.1

LAMBA variant C.37; earliest documented samples Peru (August 2020), Date of designation June 2021

LFIAs lateral flow immunoassays.

MERS Middle East Respiratory Syndrome

MMF mycophenolate mofetil

MPA mycophenolic acid

MPPDH inosine-5’-monophosphate dehydrogenase

NAAT nucleic acid amplification test

NGS Next Generation Sequencing

bNAbs Broadly neutralizing antibodies

N-IgG Anti-N-IgG

PRD Viral Prion-like domain

RBD receptor-binding domain

RBDs receptor-binding domains

RD-B-IgG receptor-binding domain neutralizing antibodies

RT-PCR real-time PCR Polymerase chain reaction

S the Spike glycoprotein

SARS-CoV-1 Severe Acute Respiratory Syndrome Coronavirus 1

SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

SARSr-CoV Rp3 salivar protein similar to fused 8a and 8b SARS-CoV Beta Coronavirus

S-IgG Antispike IgG

thio-NAD thionicotinamide-adenine dinucleotide

TNF Tumor Necrosis Factor

VIPIT prothrombotic immune thrombocytopenia

VOC Variants of Concern

VOI Variants of Interest

ZETA variant P.2

References

1. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. *Lancet* 2020, 395, 1054–1062. [CrossRef]

2. Buonanno, G.; Stabile, L.; Morawaska, L. Estimation of Airborne Viral Emission: Quanta Emission Rate of SARS-CoV-2 for Infection Risk Assessment. *Environ. Int.* 2020, 141, 105794. [CrossRef] [PubMed]

3. Meselson, M. Droplets and Aerosols in the Transmission of SARS-CoV-2. *N. Engl. J. Med.* 2020, 382, 2063. [CrossRef]

4. Scarano, A.; Inchingolo, F.; Lorusso, F. Environmental Disinfection of a Dental Clinic during the COVID-19 Pandemic: A Narrative Insight. *BioMed Res. Int.* 2020, 2020, 8896812. [CrossRef] [PubMed]

5. Isha, S.N.; Ahmad, A.; Kabir, R.; Apu, E.H. Dental Clinic Architecture Prevents COVID-19-like Infectious Diseases. *HERD Health Environ. Res. Des. J.* 2020, 13, 240–241. [CrossRef]

6. Xie, X.; Li, Y.; Sun, H.; Liu, L. Exhaled Droplets Due to Talking and Coughing. *J. R. Soc. Interface* 2009, 6 (Suppl. 6), S703–S714. [CrossRef] [PubMed]

7. Somsen, G.A.; van Rijn, C.; Kooij, S.; Bem, R.A.; Bonn, D. Small Droplet Aerosols in Poorly Ventilated Spaces and SARS-CoV-2 Transmission. *Lancet Respir. Med.* 2020, 8, 658–659. [CrossRef]

8. Karahan, S.; Katkut, F. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey. *J. Nutr. Health Aging* 2021, 25, 189–196. [CrossRef]

9. Liu, Y.; Liu, J.; Xia, H.; Zhang, X.; Fontes-Garfias, C.R.; Swanson, K.A.; Cai, H.; Sarkar, R.; Chen, W.; Cutler, M.; et al. Neutralizing Activity of BNT162b2-Elicited Serum—Preliminary Report. *N. Engl. J. Med.* 2021, 384, 1466–1468. [CrossRef]

10. To, K.K.-W.; Tsang, O.T.-Y.; Leung, W.-S.; Tam, A.R.; Wu, T.-C.; Lung, D.C.; Yip, C.C.-Y.; Cai, J.-P.; Chan, J.M.-C.; Chik, T.S.-H.; et al. Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses during Infection by SARS-CoV-2: An Observational Cohort Study. *Lancet Infect. Dis.* 2020, 20, 565–574. [CrossRef]

11. Balzanelli, G.M.; Distratis, P.; Aityan, S.K.; Amatulli, F.; Catucci, O.; Cefalo, A.; Dipalma, G.; Inchingolo, F.; Lazzaro, R.; Nguyen, K.C.D.; et al. COVID-19 and COVID-like Patients: A Brief Analysis and Findings of Two Deceased Cases. *Open Access Maced. J. Med. Sci.* 2020, 8, 490–495. [CrossRef]

12. Tetz, G.; Tetz, V. Prion-Like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2. *Microorganisms* 2022, 10, 280. [CrossRef] [PubMed]
13. Self, W.H.; Tenforde, M.W.; Rhoads, J.P.; Gagliani, M.; Ginde, A.A.; Douin, D.J.; Olson, S.M.; Talbot, H.K.; Casey, J.D.; Mohr, N.M.; et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions—United States, March–August 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1337–1343. [CrossRef] [PubMed]

14. Thompson, M.G.; Burgess, J.L.; Naleway, A.L.; Tyner, H.; Yoon, S.K.; Meeco, J.; Olsho, L.E.W.; Caban-Martinez, A.J.; Fowlkes, A.L.; Lutrick, K.; et al. Prevention and Attenuation of COVID-19 with the BNT162b2 and MRNA-1273 Vaccines. N. Engl. J. Med. 2021, 385, 320–329. [CrossRef] [PubMed]

15. Tenforde, M.W.; Self, W.H.; Naioti, E.A.; Ginde, A.A.; Douin, D.J.; Olson, S.M.; Talbot, H.K.; Casey, J.D.; Mohr, N.M.; Zepeski, R.; et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults—United States, March–July 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1156–1162. [CrossRef] [PubMed]

16. Nanduri, S.; Pilishvili, T.; Derado, G.; Soe, M.M.; Dollard, P.; Wu, H.; Li, Q.; Bagchi, S.; Dubendris, H.; Link-Gelles, R.; et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant—National Healthcare Safety Network, 1 March–1 August 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1163–1166. [CrossRef] [PubMed]

17. Eyre, D.W.; Taylor, D.; Purver, M.; Chapman, D.; Fowler, T.; Pouwels, K.B.; Walker, A.S.; Peto, T.E.A. The Impact of SARS-CoV-2 Vaccination on Alpha & Delta Variant Transmission. medRxiv 2021. [CrossRef]

18. Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection. Nat. Med. 2021, 27, 1205–1211. [CrossRef]

19. Janeway, C.A., Jr; Travers, P.; Walport, M.; Shlomchik, M.J. Immunobiology: The Immune System in Health and Disease, 5th ed.; Garland Science: New York, NY, USA, 2001.

20. William, P.E. Fundamental Immunology, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2003.

21. Humphrey, J.H.; White, R.G. Immunology for Students of Medicine, 3rd ed.; Humphrey, J.H.; White, R.G. Blackwell Scientific: Oxford, UK, 1970; pp. 65–100.

22. Webster, A.D. Primary Immunodeficiency. Hum. Exp. Toxicol. 1995, 14, 99–100. [CrossRef]

23. Balzanelli, M.G.; Distrits, P.; Lazzaro, R.; Cefalo, A.; Catucci, O.; Aityan, S.K.; Dipalma, G.; Inchingolo, A.D.; Maggiore, M.E.; et al. The Vitamin D, IL-6 and the EGFR Markers a Possible Way to ELicudate the Lung–Heart–Kidney Cross-Talk in COVID-19 Disease: A Foregone Conclusion. Microorganisms 2021, 9, 1903. [CrossRef] [PubMed]

24. Phan, D.Q.; Nguyen, L.D.N.; Pham, S.T.; Nguyen, T.; Pham, P.T.T.; Nguyen, S.T.H.; Pham, D.T.; Pham, H.T.; Tran, D.K.; Le, S.H.; et al. The Distribution of Dengue Virus Serotype in Quang Nam Province (Vietnam) during the Outbreak in 2018. Int. J. Environ. Res. Public Health 2022, 19, 1285. [CrossRef] [PubMed]

25. Maglione, M.; Bevilacqua, L.; Dotto, F.; Costantinides, F.; Lorusso, F.; Scarano, A. Observational Study on the Preparation of the Implant Site with Piezosurgery vs. Drill: Comparison between the Two Methods in Terms of Postoperative Pain, Surgical Times, and Operational Advantages. BioMed Res. Int. 2019, 2019, 8483658. [CrossRef] [PubMed]

26. Interim Statement on Booster Doses for COVID-19 Vaccination. Available online: https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination (accessed on 6 November 2021).

27. CDC. CDC COVID-19 Booster Shot. Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html (accessed on 6 November 2021).

28. Montenegro, V.; Inchingolo, A.D.; Malcangi, G.; Limongelli, L.; Marinelli, G.; Coloccia, G.; Lautadio, C.; Patano, A.; Inchingolo, F.; Bordea, I.R.; et al. Compliance of Children with Removable Functional Appliance with Microchip Integrated during COVID-19 Pandemic: A Systematic Review. J. Biol. Regul. Homeost. Agents 2021, 35, 365–377. [PubMed]

29. Booster Shots and Third Doses for COVID-19 Vaccines: What You Need to Know. Available online: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/booster-shots-and-third-doses-for-covid19-vaccines-what-you-need-to-know (accessed on 6 November 2021).

30. Malcangi, G.; Inchingolo, A.D.; Inchingolo, A.M.; Santacroce, L.; Marinelli, G.; Mancini, A.; Vimercati, L.; Maggiore, M.E.; D’oria, M.T.; Hassballa, D.; et al. COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. Microorganisms 2021, 9, 1964. [CrossRef]

31. Ballini, A.; Santacroce, L.; Cantore, S.; Botalico, L.; Dipalma, G.; Vito, D.D.; Saini, R.; Inchingolo, F. Probiotics Improve Urogenital Health in Women. Open Access Maced. J. Med. Sci. 2018, 6, 1845–1850. [CrossRef]

32. Santacroce, L.; Inchingolo, A.D.; Topi, S.; Del Prete, R.; Di Cosola, M.; Charitos, I.A.; Montagnani, M. Potential Beneficial Role of Probiotics on the Outcome of COVID-19 Patients: An Evolving Perspective. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 295–301. [CrossRef]

33. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. BNT162b2 Vaccine Booster Dose Protection: A Nationwide Study from Israel. N. Engl. J. Med. 2021. [CrossRef]

34. Shapiro Ben David, S.; Shamir-Stein, N.; Baruch Gez, S.; Lerner, U.; Rahamin-Cohen, D.; Ekka Zohar, A. Reactogenicity of a Third BNT162b2 mRNA COVID-19 Vaccine among Immunocompromised Individuals and Seniors—A Nationwide Survey. Clin. Immunol. 2021, 232, 108860. [CrossRef]
35. Bensouna, I.; Caudwell, V.; Kubab, S.; Acquaviva, S.; Pardon, A.; Vittoz, N.; Bozman, D.-F.; Hanafi, L.; Faucon, A.-L.; Housset, P. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. Am. J. Kidney Dis. 2021, 79, 185–192.e1. [CrossRef]

36. Balzanelli, M.G.; Distratis, P.; Dipalma, G.; Vimercati, L.; Catucci, O.; Amatulli, F.; Cefalo, A.; Lazzaro, R.; Palazzo, D.; Aityan, S.K.; et al. Immunity Profiling of COVID-19 Infection, Dynamic Variations of Lymphocyte Subsets, a Comparative Analysis on Four Different Groups. Microorganisms 2021, 9, 2036. [CrossRef]

37. Vomero, M.; Barbati, C.; Colasanti, T.; Celia, A.I.; Speziali, M.; Ucci, F.M.; Ciancarella, C.; Conti, F.; Alessandrini, C. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-CoV-2 Infection. Front. Pharmacol. 2020, 11, 569849. [CrossRef] [PubMed]

38. Bordea, I.R.; Xhajanka, E.; Candrea, S.; Bran, S.; Onis, F.; Inchingolo, A.D.; Malcangi, G.; Pham, V.H.; Inchingolo, A.M.; Scarano, A.; et al. Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. Microorganisms 2020, 8, 1704. [CrossRef] [PubMed]

39. Bellocchio, L.; Bordea, I.R.; Ballini, A.; Lorusso, F.; Hazballa, D.; Isacco, C.G.; Malcangi, G.; Inchingolo, A.D.; Dipalma, G.; Inchingolo, F.; et al. Environmental Issues and Neurological Manifestations Associated with COVID-19 Pandemic: New Aspects of the Disease? Int J. Environ. Res. Public Health 2020, 17, 8049. [CrossRef] [PubMed]

40. Turner, J.S.; Kim, W.; Kalaidina, E.; Goss, C.W.; Rauseo, A.M.; Schmitz, A.J.; Hansen, L.; Haile, A.; Klebert, M.K.; Pusic, L.; et al. SARS-CoV-2 Infection Induces Long-Lived Bone Marrow Plasma Cells in Humans. Nature 2021, 595, 421–425. [CrossRef] [PubMed]

41. Algaissi, A.; Alfaleh, M.A.; Hala, S.; Abujameil, T.S.; Alamri, S.S.; Almahboub, S.A.; Alluhaybi, K.A.; Hobani, H.I.; Alsaluaiman, R.M.; AlHarbi, R.H.; et al. SARS-CoV-2 S and N-Based Serological Assays Reveal Rapid Seroconversion and Induction of Specific Antibody Response in COVID-19 Patients. Sci Rep. 2020, 10, 16561. [CrossRef]

42. Balzanelli, M.G.; Distratis, P.; Aityan, S.K.; Amatulli, F.; Catucci, O.; Cefalo, A.; De Michele, A.; Dipalma, G.; Inchingolo, F.; Lazzaro, R.; et al. An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology. Endocr. Metab. Immune Disord. Drug Targets 2022, 22, 1–5. [CrossRef]

43. Inchingolo, A.D.; Inchingolo, A.M.; Bordea, I.R.; Malcangi, G.; Xhajanka, E.; Scarano, A.; Lorusso, F.; Farronato, M.; Tartaglia, G.M.; Isacco, C.G.; et al. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. Microorganisms 2021, 9, 525. [CrossRef] [PubMed]

44. Inchingolo, A.D.; Dipalma, G.; Inchingolo, A.M.; Malcangi, G.; Santacroce, L.; D’oria, M.T.; Isacco, C.G.; Bordea, I.R.; Candrea, S.; Scarano, A.; et al. The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. Antioxidants 2021, 10, 881. [CrossRef]

45. Rapone, B.; Ferrara, E.; Corsalini, M.; Quorri, E.; Converti, I.; Lorusso, F.; Delvecchio, M.; Gnoni, A.; Scacco, S.; Scarano, A. Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial. Int. J. Environ. Res. Public Health 2021, 18, 3018. [CrossRef]

46. Corsalini, M.; Di Venere, D.; Sportelli, P.; Magazzino, D.; Ripa, C.; Cantatore, F.; Cagnetta, G.; De Rinaldis, C.; Montemurro, N.; De Giacomo, A. Evaluation of prosthetic quality and masticatory efficiency in patients with total removable prosthesis study of 12 cases. ORAL Implantol. 2018, 11, 230–240. [CrossRef]

47. Grassi, F.R.; Grassi, R.; Rapone, B.; Alemanno, G.; Balena, A.; Kalemaj, Z.; Gianfranco, A. Dimensional Changes of Buccal Bone Plate in Immediate Implants Inserted through Open Flap, Open Flap and Bone Grafting and Flapless Techniques: A Cone-Beam Computed Tomography Randomized Controlled Clinical Trial. Clin. Oral Implant. Res. 2019, 30, 1155–1164. [CrossRef] [PubMed]

48. Quaglia, E.; Moscufo, L.; Corsalini, M.; Coscia, D.; Sportelli, P.; Cantatore, F.; De Rinaldis, C.; Rapone, B.; Carossa, M.; Carossa, S. Polyamide vs Silk Sutures in the Healing of Postextraction Sockets: A Split Mouth Study. Oral Implantol. 2018, 11, 115–120. [CrossRef]

49. Rapone, B.; Ferrara, E.; Santacroce, L.; Cesarino, F.; Arazzi, M.; Liberato, L.D.; Scacco, S.; Grassi, R.; Grassi, F.R.; Gnoni, A.; et al. Periodontal Microbiological Status Influences the Occurrence of Cyclosporine-A and Tacrolimus-Induced Gingival Overgrowth. Antibiotics 2019, 8, 124. [CrossRef] [PubMed]

50. Rapone, B.; Converti, I.; Santacroce, L.; Cesarino, F.; Vecchiet, F.; Caciolo, L.; Scacco, S.; Grassi, R.; Grassi, F.R.; Gnoni, A.; et al. Impact of Periodontal Inflammation on Nutrition and Inflammation Markers in Hemodialysis Patients. Antibiotics 2019, 8, 209. [CrossRef]

51. Lorusso, F.; Noumbissi, S.; Franceschi, I.; Rapone, B.; Khater, A.G.A.; Scarano, A. Scientific Trends in Clinical Research on Zirconia Dental Implants: A Bibliometric Review. Materials 2020, 13, 5534. [CrossRef]

52. Corsalini, M.; Di Venere, D.; Carossa, M.; Ripa, M.; Sportelli, P.; Cantatore, F.; De Rinaldis, C.; Di Santantonio, G.; Lenoci, G.; Barile, G. Comparative clinical study between zirconium-ceramic and metal-ceramic fixed rehabilitations. ORAL Implantol. 2018, 11, 150–160. [CrossRef]

53. Baum, A.; Fulton, B.O.; Wloda, E.; Copin, R.; Pascal, K.E.; Russo, V.; Giordano, S.; Lanza, K.; Negron, N.; Ni, M.; et al. Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies. Science 2020, 369, 1014–1018. [CrossRef]

54. Schäfer, A.; Muecksch, F.; Lorenzi, J.C.C.; Leist, S.R.; Cippola, M.; Bourazos, S.; Schmidt, F.; Maison, R.M.; Gazumyan, A.; Martínez, D.R.; et al. Antibody Potency, Effector Function and Combinations in Protection from SARS-CoV-2 Infection in Vivo. J. Exp. Med. 2021, 218, e20201993. [CrossRef]
76. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 Vaccine Booster against COVID-19 in Israel. *N. Engl. J. Med.* 2021, 385, 1393–1400. [CrossRef] [PubMed]

77. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological Memory to SARS-CoV-2 Assessed for up to 8 Months after Infection. *Science* 2021, 371, eabf4063. [CrossRef] [PubMed]

78. Rana, R.; Ranjan, V.; Kumar, N. Association of ABO and Rh Blood Group in Susceptibility, Severity, and Mortality of Coronavirus Disease 2019: A Hospital-Based Study from Delhi, India. *Front. Cell Infect. Microbiol.* 2021, 11, 767771. [CrossRef]

79. Janda, A.; Engel, C.; Remppis, J.; Enkel, S.; Peter, A.; Hörber, S.; Ganzenmueller, T.; Jacobson, E.-M.; et al. Role of ABO Blood Group in SARS-CoV-2 Infection in Households. *Front. Microbiol.* 2022, 13, 857965. [CrossRef] [PubMed]

80. Shachor-Meyouhas, Y.; Hussein, K.; Dabaja-Younis, H.; Szwarcwort-Cohen, M.; Almog, R.; Weissman, A.; Mekel, M.; Hyams, G.; Horowitz, N.A.; Gepstein, V.; et al. Immunogenicity Trends 1 and 3 Months after Second BNT162b2 Vaccination among Healthcare Workers in Israel. *Clin. Microbiol. Infect.* 2021, 27, 450.e1–450.e4. [CrossRef]

81. Israel, A.; Shenhar, Y.; Green, I.; Merzon, E.; Golan-Cohen, A.; Schäffer, A.A.; Ruppin, E.; Vinker, S.; Magen, E. Large-Scale Study of Antibody Titer Decay Following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. *medRxiv* 2021, 10, 64. [CrossRef]

82. Sudre, C.H.; Murray, B.; Varsavsky, T.; Graham, M.S.; Penfold, R.S.; Bowyer, R.C.; Pujol, J.C.; Klas, K.; Antonelli, M.; Canas, L.S.; et al. Attributes and Predictors of Long COVID. *Nat. Med.* 2021, 27, 626–631. [CrossRef] [PubMed]

83. Burnham, E.L.; Janssen, W.J.; Riches, D.W.H.; Moss, M.; Downey, G.P. The Fibroproliferative Response in Asymptomatic and Mildly Affected Patients. *Emerg. Infect. Dis.* 2020, 26, 1834–1838. [CrossRef]

84. Doykov, I.; Hällqvist, J.; Gilmour, K.C.; Grandjean, L.; Schober, S.; Weinstock, C.; Jacobson, E.-M.; et al. The Long Tail of COVID-19—The Detection of a Distress Syndrome: Mechanisms and Clinical Significance. *Eur. Respir. J.* 2014, 43, 276–285. [CrossRef] [PubMed]

85. Giovannetti, G.; De Michele, L.; Pierucci, P.; Mirabile, A.; Vita, M.; Palmigrano, G.E.; Scardapane, A.; D’Agostino, C. Lung Ultrasonography for Long-Term Follow-up of COVID-19 Survivors Compared to Chest CT Scan. *Respir. Med.* 2021, 181, 106364. [CrossRef]

86. Umercati, L.; Maria, L.D.; Quarato, M.; Caputi, A.; Gesualdo, L.; Migliore, G.; Grifoni, A.; Sponselli, S.; Pipoli, A.; Inchingolo, F.; et al. Association between Long COVID and Overweight/Obesity. *J. Clin. Med.* 2021, 10, 4143. [CrossRef] [PubMed]

87. Nath, A. Long-Haul COVID. *Neurology* 2022, 87. Nath, A. Long-Haul COVID. *Neurology* 2022, 87. [CrossRef]

88. Silva Andrade, B.; Siqueira, S.; de Assis Soares, W.R.; de Souza Rangel, F.; Santos, N.O.; dos Santos Freitas, A.; Ribeiro da Silveira, Inchingolo, F.; Charitos, I.A.; Ballini, A.; Inchingolo, F.; Luperto, P.; De Nitto, E.; Topi, S. The Human Respiratory System and Its Microbiome at a Glimpse. *Biology* 2020, 9, 318. [CrossRef]

89. Santacroce, L.; Charitos, I.A.; Ballini, A.; Inchingolo, F.; Luperto, P.; De Nitto, E.; Topi, S. The Human Respiratory System and Its Microbiome at a Glimpse. *Biology* 2020, 9, 318. [CrossRef] [PubMed]

90. Proal, A.D.; VanElzakker, M.B. Long COVID or Post-Acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. *Front. Microbiol.* 2021, 12, 698169. [CrossRef]

91. Belizario, J.E.; Faintuch, J. Microbiome and Gut Dysbiosis. *Exp. Suppl.* 2018, 109, 459–476. [CrossRef] [PubMed]

92. Horner, M. Pathogens, Commensal Symbionts, and Pathobionts: Discovery and Functional Effects on the Host. *ILAR J.* 2014, 56, 159–162. [CrossRef]

93. Sun, J.; Xiao, J.; Sun, R.; Tang, X.; Liang, C.; Lin, H.; Zeng, L.; Hu, J.; Yuan, R.; Zhou, P.; et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. *Emerg. Infect. Dis.* 2020, 26, 1834–1838. [CrossRef]

94. Kapone, B.; Ferrara, E.; Santacroce, L.; Topi, S.; Gnini, A.; Dipalma, G.; Mancini, A.; Di Domenico, M.; Tartaglia, G.M.; Scarano, A.; et al. The Gaseous Ozone Therapy as a Promising Antiseptic Adjuvant of Periodontal Treatment: A Randomized Controlled Clinical Trial. *Int. J. Environ. Res. Public Health* 2022, 19, 985. [CrossRef]